RxSight, Inc. confirmed that Chief Financial Officer Shelley Thunen will step down from her role, remaining with the company until the earlier of her successor’s appointment or January 31, 2026. She will continue to support the business as a consultant, ensuring a smooth handover of financial leadership.
Thunen’s decade‑long tenure has been pivotal to RxSight’s growth. Under her stewardship the company moved from a pre‑commercial stage to installing more than 1,100 Light Delivery Devices (LDDs) and performing over 250,000 Light Adjustable Lens (LAL) procedures, milestones that have driven the company’s market penetration and revenue streams.
CEO Ron Kurtz highlighted Thunen’s role in crafting the financial strategy that underpinned RxSight’s expansion. He said the transition is part of a broader strategic realignment aimed at maximizing LAL utilization and strengthening the company’s competitive position in the premium cataract market.
The announcement comes after RxSight reported a 14% year‑over‑year decline in revenue for Q3 2025 and a net loss of $9.8 million, underscoring the challenges the company faces as it scales its technology and navigates a competitive landscape.
Investors reacted negatively to the CFO transition, reflecting concerns about leadership continuity and the potential impact on financial oversight during a period of strategic change.
The company’s focus on expanding LAL adoption and its commitment to a seamless transition suggest confidence in its long‑term strategy, but the CFO departure signals a shift in the leadership team that may influence investor perception of the company’s financial stability.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.